Uspeshnyy klinicheskiy opyt primeneniya gennoy i kletochnoy terapii tyazhelogo kombinirovannogo immunodefitsita, vyzvannogo nedostatkom adenozindezaminazy

References

[1] Hirschorn R., Candotti F. Immunodeficiency due to defects of purine metabolism. In: Ochs H, Smith C, Puck J, eds. Primary immunodeficiency diseases. Oxford, England: Oxford University Press, 2006: 169-96.

[2] Hershfield M.S. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol. 1998; 35:291-8.

[3] Rogers M.H., Lwin R., Fairbanks L. et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J. Pediatr. 2001;139:44-50.

[4] Hoenig M., Albert M.H., Schulz A. et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007; 109: 3595-602.

[5] Antoine C, Mueller S., Cant A. et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003; 361: 553-60.

[6] Grunebaum E., Mazzolari E., Porta F. et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295: 508-18.

[7] Malacarne F., Benicchi Т., Notarangelo L.D. et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal В cells in polyethylene glycol-adenosine deaminase-treated patients. Eur. J. Immunol. 2005; 35: 3376-86.

[8] Chan В., Wara D., Bastian J. et al. Long term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin. Immunol. 2005; 117: 133-43.

[9] Bordignon C, Notarangelo L.D., Nobili N. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADAmmunodeficient patients. Science 1995; 270: 470-5.

[10] Blaese R.M., Culver K.W., Miller A.D. et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-80.

[11] Kohn D.B., Hershfield M.S., Carbonaro D. et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 1998; 4: 775-80.

[12] Aiuti A., Slavin S., Aker M. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-3.

[13] Booth C, Hershfield M., Notarangelo L. et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin. Immunol. 2007; 123: 139-47.

[14] Gaspar H.B., Bjorkegren E., Parsley K. et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 2006; 14: 505-13.

RIGHTS & PERMISSIONS

Eco-Vector